{"id":37,"date":"2025-03-05T12:35:18","date_gmt":"2025-03-05T11:35:18","guid":{"rendered":"https:\/\/ketamin.no\/?page_id=37"},"modified":"2025-06-30T11:33:44","modified_gmt":"2025-06-30T09:33:44","slug":"angst","status":"publish","type":"page","link":"https:\/\/ketamin.no\/angst\/","title":{"rendered":"Ketamin Angst"},"content":{"rendered":"\n<div class=\"wp-block-cover alignfull is-light has-parallax is-style-default\" style=\"margin-top:0;margin-bottom:0;padding-top:var(--wp--preset--spacing--xxx-large);padding-right:0;padding-bottom:var(--wp--preset--spacing--xxx-large);padding-left:0\"><div class=\"wp-block-cover__image-background wp-image-334 has-parallax\" style=\"background-position:50% 50%;background-image:url(https:\/\/ketamin.no\/app\/uploads\/2025\/03\/Ketamin-angst.jpeg)\"><\/div><span aria-hidden=\"true\" class=\"wp-block-cover__background has-main-background-color has-background-dim-0 has-background-dim\"><\/span><div class=\"wp-block-cover__inner-container is-layout-flow wp-block-cover-is-layout-flow\">\n<div class=\"wp-block-group alignfull has-global-padding is-layout-constrained wp-container-core-group-is-layout-2a1d1525 wp-block-group-is-layout-constrained\" style=\"margin-top:0px;margin-bottom:0px;padding-right:var(--wp--preset--spacing--medium);padding-left:var(--wp--preset--spacing--medium)\">\n<div class=\"wp-block-columns alignwide are-vertically-aligned-center is-layout-flex wp-container-core-columns-is-layout-83ee8993 wp-block-columns-is-layout-flex\" style=\"margin-top:0px;margin-bottom:0px\">\n<div class=\"wp-block-column is-vertically-aligned-center is-layout-flow wp-block-column-is-layout-flow\">\n<div class=\"wp-block-group has-global-padding is-layout-constrained wp-container-core-group-is-layout-b56e0895 wp-block-group-is-layout-constrained\">\n<h2 class=\"wp-block-heading alignfull has-text-align-center has-primary-color has-text-color\">Ketaminbehandling <strong>for angst<\/strong>lidelser<\/h2>\n\n\n\n<p class=\"has-text-align-center has-primary-color has-text-color has-medium-font-size wp-block-paragraph\">Ketamin har f\u00e5tt \u00f8kende oppmerksomhet som behandling for angstlidelser, spesielt for pasienter der tradisjonelle behandlingsmetoder som SSRI, SNRI og kognitiv atferdsterapi ikke har hatt tilstrekkelig effekt. Flere studier har vist at ketamin kan gi rask symptomlindring, ofte innen timer til dager, noe som skiller det fra tradisjonelle medikamentelle behandlingsalternativer.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n<div class=\"wp-block-group has-global-padding is-layout-constrained wp-container-core-group-is-layout-03cab32d wp-block-group-is-layout-constrained\" style=\"padding-top:var(--wp--preset--spacing--medium);padding-right:var(--wp--preset--spacing--medium);padding-bottom:var(--wp--preset--spacing--medium);padding-left:var(--wp--preset--spacing--medium)\">\n<h3 class=\"wp-block-heading\">Virkningsmekanisme<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Ketamin skiller seg fra konvensjonelle angstdempende medikamenter ved at det prim\u00e6rt virker p\u00e5 glutamaterge signalveier, spesielt via NMDA-reseptorer. Dette kan f\u00f8re til \u00f8kt nevroplastisitet, forbedret affektregulering og reduksjon av angst. I tillegg kan ketamin redusere unng\u00e5elsesatferd og bidra til \u00e5 bryte fastl\u00e5ste tanke- og handlingsm\u00f8nstre, noe som er sentralt i mange angstlidelser.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Inklusjonskriterier<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">For \u00e5 v\u00e6re aktuell for ketaminbehandling m\u00e5 pasienten med angstlidelser oppfylle visse kriterier. De viktigste kriteriene er:&nbsp;<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Diagnostisert angstlidelse, som generalisert angst (GAD), sosial fobi, tvangslidelse (OCD) og posttraumatisk stresslidelse (PTSD).<\/li>\n\n\n\n<li>Tidligere behandling: Pasienten m\u00e5 ha pr\u00f8vd antidepressiva og psykologbehandling uten tilfredsstillende effekt. Dersom pasienten har reservasjoner mot antidepressiva kan ketamin allikevel vurderes.&nbsp;<\/li>\n\n\n\n<li>Fysisk helse: Pasienten m\u00e5 v\u00e6re i stabil somatisk tilstand uten ukontrollerte kardiovaskul\u00e6re, nevrologiske eller metabolske lidelser.<\/li>\n\n\n\n<li>Psykisk helse: Frav\u00e6r av psykose og alvorlig ustablitet.<\/li>\n\n\n\n<li>Sikkerhet: Pasienten m\u00e5 v\u00e6re motivert for behandling og samarbeide om n\u00f8dvendig oppf\u00f8lging og evaluering.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Individuell vurdering gj\u00f8res i hvert tilfelle, og behandlingen tilpasses pasientens behov og respons.<\/p>\n\n\n\n<div class=\"wp-block-group has-base-color has-primary-background-color has-text-color has-background has-global-padding is-layout-constrained wp-container-core-group-is-layout-a3874c0f wp-block-group-is-layout-constrained\" style=\"border-radius:5px;padding-top:var(--wp--preset--spacing--large);padding-right:var(--wp--preset--spacing--large);padding-bottom:var(--wp--preset--spacing--large);padding-left:var(--wp--preset--spacing--large)\">\n<h3 class=\"wp-block-heading has-text-align-center has-primary-accent-color has-text-color has-link-color wp-elements-c94b363d7e4cc357f360073b86d4dd27\">Ketaminassistert psykoterapi<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Ketaminassistert psykoterapi inneb\u00e6rer at samtaleterapi kombineres med medisiner, der ketamin administreres et f\u00e5tall ganger for \u00e5 optimalisere effekten av terapien. Behandlingen kan:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Fremme nevroplastisitet og lette endring av fastl\u00e5ste tanke- og handlingsm\u00f8nstre.<\/li>\n\n\n\n<li>Forbedre effekten av samtaleterapi hos pasienter som ikke har hatt tilstrekkelig nytte av tradisjonell behandling.<\/li>\n\n\n\n<li>Redusere p\u00e5trengende negative tanker og gi \u00f8kt motivasjon til endring.<\/li>\n\n\n\n<li>Skape en opplevelse av h\u00e5p og \u00f8kt livskvalitet.<\/li>\n\n\n\n<li>Gir \u00f8kt tilgang og toleranse for egne f\u00f8lelser<\/li>\n<\/ul>\n<\/div>\n\n\n\n<div class=\"wp-block-group has-global-padding is-layout-constrained wp-block-group-is-layout-constrained\">\n<h3 class=\"wp-block-heading\">Bivirkninger og sikkerhet<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Ketaminbehandling b\u00f8r administreres i en klinisk setting med adekvat monitorering. Vanlige akutte forbig\u00e5ende bivirkninger inkluderer:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Forbig\u00e5ende dissosiasjon og perseptuelle endringer.<\/li>\n\n\n\n<li>Forbig\u00e5ende blodtrykks\u00f8kning.<\/li>\n\n\n\n<li>Svimmelhet, kvalme og hodepine.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Dokumentasjon og kliniske studier<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Flere randomiserte studier har vist at lavdose ketamin kan gi betydelig reduksjon i angstsymptomer.<\/p>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-group has-border-light-background-color has-background has-global-padding is-layout-constrained wp-container-core-group-is-layout-cb36a28f wp-block-group-is-layout-constrained\" style=\"margin-top:var(--wp--preset--spacing--medium);margin-bottom:var(--wp--preset--spacing--medium);padding-top:var(--wp--preset--spacing--large);padding-right:var(--wp--preset--spacing--medium);padding-bottom:var(--wp--preset--spacing--large);padding-left:var(--wp--preset--spacing--medium)\">\n<h3 class=\"wp-block-heading\">Vitenskapelige artikler<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Generalisert angstlidelse (GAD) og sosial angstlidelse (SAD)<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/28441895\/\" target=\"_blank\" rel=\"noopener nofollow\" title=\"\">Glue, P., Medlicott, N., Harland, S., Neehoff, S., Anderson-Fahey, B., Le Nedelec, M., &amp; Wilson, D. (2017). Ketamine\u2019s dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. <em>Journal of Psychopharmacology, 31<\/em>(10), 1302-1305.<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/28849779\/\" target=\"_blank\" rel=\"noopener nofollow\" title=\"\">Taylor, J., &amp; Lander, M. (2017). Ketamine for social anxiety disorder: a randomized, placebo-controlled crossover trial. <em>Neuropsychopharmacology, 42<\/em>(12), 2417-2425.<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31339086\/\" target=\"_blank\" rel=\"noopener nofollow\" title=\"\">Banov MD, Young JR, Dunn T, Szabo ST. Efficacy and safety of ketamine in the management of anxiety and anxiety spectrum disorders: a review of the literature. <em>CNS Spectr.<\/em> 2020;25(3):331-342<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36519357\/\" target=\"_blank\" rel=\"noopener nofollow\" title=\"\">Caldiroli A, Capuzzi E, Tagliabue I, Ledda L, Clerici M, Buoli M. New frontiers in the pharmacological treatment of social anxiety disorder in adults: an up-to-date comprehensive overview. <em>Expert Opin Pharmacother.<\/em>2023;24(2):207-219.<\/a><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Tvangslidelse (OCD)<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/23783065\/\" target=\"_blank\" rel=\"noopener nofollow\" title=\"\">Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D., \u2026 &amp; Simpson, H. B. (2013). Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. <em>Neuropsychopharmacology, 38<\/em>(12), 2475-2483.<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/22784486\/\" target=\"_blank\" rel=\"noopener nofollow\" title=\"\">Bloch, M. H., Wasylink, S., Landeros-Weisenberger, A., Panza, K. E., Billingslea, E., Leckman, J. F., &amp; Krystal, J. H. (2012). Effects of ketamine in treatment-refractory obsessive-compulsive disorder. <em>Biological Psychiatry, 72<\/em>(11), 964-970.<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39609659\/\" target=\"_blank\" rel=\"noopener nofollow\" title=\"\">Beaglehole B, Glue P, Neehoff S, et al. Ketamine for treatment-resistant obsessive-compulsive disorder: Double-blind active-controlled crossover study. <em>J Psychopharmacol.<\/em> 2025;39(1):23-28.<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39899368\/\" target=\"_blank\" rel=\"noopener nofollow\" title=\"\">Ishimuro HS, Yanes-Lukin PK, Goldberg PH, Simpson HB, Rynn MA. Ketamine Treatment for Pediatric Refractory Obsessive: Five Open Label Cases. <em>J Child Adolesc Psychopharmacol.<\/em> 2025.<\/a><\/li>\n<\/ul>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Virkningsmekanisme Ketamin skiller seg fra konvensjonelle angstdempende medikamenter ved at det prim\u00e6rt virker p\u00e5 glutamaterge signalveier, spesielt via NMDA-reseptorer. Dette kan f\u00f8re til \u00f8kt nevroplastisitet, forbedret affektregulering og reduksjon av angst. I tillegg kan ketamin redusere unng\u00e5elsesatferd og bidra til \u00e5 bryte fastl\u00e5ste tanke- og handlingsm\u00f8nstre, noe som er sentralt i mange angstlidelser. Inklusjonskriterier For [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page-no-title","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-37","page","type-page","status-publish","hentry"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/ketamin.no\/api\/wp\/v2\/pages\/37","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ketamin.no\/api\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/ketamin.no\/api\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/ketamin.no\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ketamin.no\/api\/wp\/v2\/comments?post=37"}],"version-history":[{"count":0,"href":"https:\/\/ketamin.no\/api\/wp\/v2\/pages\/37\/revisions"}],"wp:attachment":[{"href":"https:\/\/ketamin.no\/api\/wp\/v2\/media?parent=37"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}